,31 However, as KEAP1 mutations frequently co-occur with STK11 mutations in clinical samples, which is also known to modulate the tumor immune milieu,23,32,33 these clinical observations suggest that NRF2 may act collaboratively with STK11 to cause the lower-level immune cell infiltrations in the tumors. The gene discussed is STK11; the disease is neoplasm.